According to Peter A. McCullough, MD, MPH, paxlovid, a dual-action antiviral medication from Pfizer that combines ritonavir and nirmatrelvir, produced variable outcomes in acute COVID-19 patients. The CDC issued a health advisory regarding paxlovid’s potential to prolong the COVID-19 sickness with rebound.
Refreshingly, what was expected of her was the same thing that was expected of Lara Stone: to take a beautiful picture.
The body’s buildup of SARS-CoV-2 Spike protein and vaccination causes long-term COVID-19. If patients do not receive treatment promptly, they may experience substantially worse outcomes from long-term COVID-19 later on as a result of invasive viral illness and Spike protein accumulation.
In clinical practice, treating this long-standing problem takes a year or longer. It should not be shocking that, in 99% of vaccinated patients—of whom 73% had no early treatment for acute COVID-19 and suffered for nine months with long-COVID—a randomized study of 15 days of Paxlovid would be doomed to failure. The US HHS National Action Plan on Long COVID-19 wasted $1 billion on pointless research programs, as demonstrated by the STOP-PASC study.
Of the 155 participants, 102 were randomized to the NMV/r group and 53 to the PBO/r group.
The participants’ median [IQR] age was 43 [34-54] years, and 92 [59%] were female. Almost all of the participants (n = 153) had undergone the COVID-19 primary set of vaccinations. There was no statistically significant difference between the NMV/r and PBO/r groups in the model-derived severity outcome summed over the six core symptoms at 10 weeks. The Patient Global Impression of Severity or Patient Global Impression of Change scores, summative symptom scores, and changes in PROMIS fatigue, dyspnea, cognitive function, and physical function measures from baseline to 10 weeks did not show any statistically significant between-group differences. In the NMV/r and PBO/r groups, adverse event rates were comparable and primarily of low grade.
10 weeks did not show any statistically significant between-group differences. In the NMV/r and PBO/r groups, adverse event rates were comparable and primarily of low grade.
According to McCullough, all long-term COVID therapies that do not target the Spike protein and its thrombotic and inflammatory pathways will be ineffective. McCullough maintains that it’s best to stick with Protocol Base Spike Detoxification as the primary strategy and adjust the dosage of prescription medications or additional supplements based on the clinical syndrome.
